Omnicell, Inc. (NASDAQ:OMCL) Forecasted to Post Q2 2024 Earnings of $0.00 Per Share

Omnicell, Inc. (NASDAQ:OMCL) – Stock analysts at Zacks Research dropped their Q2 2024 earnings per share estimates for Omnicell in a research report issued on Tuesday, April 16th. Zacks Research analyst M. Mondal now anticipates that the company will post earnings per share of $0.00 for the quarter, down from their previous forecast of $0.07. The consensus estimate for Omnicell’s current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Omnicell’s FY2024 earnings at $0.08 EPS, Q2 2025 earnings at $0.10 EPS, Q3 2025 earnings at $0.08 EPS, Q4 2025 earnings at $0.12 EPS, FY2025 earnings at $0.29 EPS and Q1 2026 earnings at $0.09 EPS.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.22. Omnicell had a negative net margin of 1.78% and a positive return on equity of 3.43%. The company had revenue of $258.85 million during the quarter, compared to analysts’ expectations of $256.00 million.

OMCL has been the topic of several other reports. Barclays assumed coverage on Omnicell in a research note on Wednesday, January 3rd. They issued an “underweight” rating and a $33.00 price objective on the stock. Wells Fargo & Company lowered their price target on Omnicell from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research report on Friday, February 9th. Finally, Benchmark cut their price objective on Omnicell from $42.00 to $38.00 and set a “buy” rating for the company in a report on Friday, February 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $42.20.

Omnicell Stock Performance

NASDAQ:OMCL opened at $27.25 on Thursday. The firm has a market capitalization of $1.25 billion, a PE ratio of -60.56 and a beta of 0.76. The company has a quick ratio of 2.22, a current ratio of 2.52 and a debt-to-equity ratio of 0.48. Omnicell has a 12-month low of $25.69 and a 12-month high of $77.14. The firm has a 50-day moving average price of $27.72 and a 200 day moving average price of $33.01.

Hedge Funds Weigh In On Omnicell

Several institutional investors have recently bought and sold shares of the business. Belpointe Asset Management LLC raised its stake in shares of Omnicell by 92.2% in the first quarter. Belpointe Asset Management LLC now owns 494 shares of the company’s stock worth $29,000 after acquiring an additional 237 shares during the last quarter. Versant Capital Management Inc lifted its holdings in Omnicell by 561.4% during the 3rd quarter. Versant Capital Management Inc now owns 549 shares of the company’s stock worth $25,000 after buying an additional 466 shares in the last quarter. Covestor Ltd boosted its position in Omnicell by 424.2% in the 1st quarter. Covestor Ltd now owns 844 shares of the company’s stock valued at $109,000 after buying an additional 683 shares during the last quarter. KBC Group NV bought a new position in Omnicell in the 4th quarter valued at $38,000. Finally, State of Wyoming increased its stake in shares of Omnicell by 25.7% in the 2nd quarter. State of Wyoming now owns 1,053 shares of the company’s stock valued at $78,000 after buying an additional 215 shares during the period. Institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.